Ambry Genetics®
A TEMPUS COMPANY

Clinical Genomics Test Requisition Form - Page 1 of 6
(ExomeNext®, GenomeNext™, Exome-based Neurology Panels, and Microarray)

COMPLETE ENTIRE FORM AND SUBMIT PEDIGREE/CLINIC NOTES TO AVOID DELAYS

To submit an order via email, please send the completed test requisition form to info@ambrygen.com

COLLECTION DATE (REQUIRED)

If date of collection is not provided, three calendar days before specimen receipt will be used (for specimens stored longer than 30 days, the day of archive retrieval will be used as the date of service)

PATIENT INFORMATION

Legal Name (Last, First, MI)	Date of Birth (MM/DD/YY)	Sex Assigned at Birth ☐F ☐M	Gender (optional) ☐Man ☐Woman ☐Nonbinary ☐Self-described

Genetic Ancestry: ☐Ashkenazi Jewish ☐Asian ☐Black/African American ☐French Canadian/Cajun ☐Hispanic/Latino ☐Mediterranean ☐Middle Eastern ☐Native American ☐Pacific Islander ☐Portuguese ☐White ☐Unknown ☐Other:

MRN

Address	City	State	Zip

Mobile #	Email	Preferred Billing ☐Insurance ☐Self-pay ☐Institutional

SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)

☐ Personal history of allogenic bone marrow or peripheral stem cell transplant ☐ Current diagnosis of heme malignancy, Type:

Specimen ID: Medical Record #

**Fetal specimens, cord blood and POC will have maternal cell contamination studies added for a charge. Maternal and fetal specimen required. Please see page 4 for Maternal Cell Contamination sample submission test codes*

Collection Assistance: ☐Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient | ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™)

*** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.*

ORDERING PHYSICIAN/SENDING FACILITY (Each listed person will receive a copy of the report)

Facility Name (Facility Code)	Address	City	State /Country	Zip	Phone

Ordering Licensed Provider Name (Last, First)(Code)	NPI#	Phone	Fax	Fax/Email

ADDITIONAL RESULTS RECIPIENTS

Genetic Counselor or Other Medical Provider Name (Last, First) (Code)	Phone/Fax/Email

CONFIRMATION OF INFORMED CONSENT, PRE-TEST GENETIC COUNSELING, AND MEDICAL NECESSITY FOR GENETIC TESTING

By signing and/or submitting the order: I certify that (1) the patient has received an explanation of the purpose, risks, and benefits of the ordered test(s); (2) the ordered test(s) are medically necessary and will inform the patient's treatment plan; and (3) the patient has provided informed consent that meets the requirements of applicable law for Tempus/Ambry or its reference lab to: (a) collect and use the patient's samples (including genetic material) and health information and perform the ordered test(s); (b) obtain, receive, and release health information (including test results) as necessary for reimbursement or the processing of insurance claims; (c) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (d) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law. I agree to allow Tempus/Ambry to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider.

Signature Required for Processing Medical Professional Signature: Date:

☐ INSURANCE BILLING (Include copy of both sides of insurance card)

Patient Relation to Policy Holder? ☐Self ☐Spouse ☐Child	Name and DOB of Policy Holder (if not self)	
Insurance Company	Policy #	HMO Auth #

Special Billing Notes:

☐ INSTITUTIONAL BILLING

Facility Name ☐ *Send invoice to facility address above*

Address

Contact Name

Phone Number	E-mail/Fax

☐ PATIENT PAYMENT

☐ Check (Payable to Ambry Genetics)
☐ Credit Card (Call 949-900-5795)

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company.
For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above.

For NY Residents:

☐ I understand that New York State law requires Ambry Genetics to destroy my sample at the end of the testing process or not more than sixty days after the sample was taken. By checking this box, I agree that Ambry Genetics will instead retain my sample for at least 6 months after the testing above has been completed, and may (a) retain and use samples and health information for an indefinite period of time in accordance with applicable law; and (b) de-identify such samples and information and use and share the resulting de-identified samples and information in accordance with applicable law.

Patient Signature (I agree to terms above): Date:

Ambry Genetics®
A TEMPUS COMPANY

Patient Name: _____ DOB: _____

Clinical Genomics Test Requisition Form - Page 2 of 6

COMPLETE THIS FAMILY MEMBER INFORMATION PAGE FOR EXOMENEXT® AND GENOMENEXT™ DUO OR TRIO ORDERS, OR FOR EXOMENEXT, GENOMENEXT, OR EXOME-BASED PANEL COSEGREGATION TESTING.

All family member specimens must be received within 4 weeks of order. Otherwise test will be run as proband only.

FAMILY MEMBER #1 INFORMATION

Legal Name (Last, First, MI)	Date of Birth (MM/DD/YY)	Date of Death (If applicable)	Phone Number/Email

Sex Assigned at Birth: ☐F ☐M

Gender (optional) ☐Man ☐Woman ☐Nonbinary ☐Self-described

Genetic Ancestry: ☐Ashkenazi Jewish ☐Asian ☐Black/African American ☐French Canadian/Cajun ☐Hispanic/Latino ☐Mediterranean ☐Middle Eastern ☐Native American ☐Pacific Islander ☐Portuguese ☐White ☐Unknown ☐Other:

Address: ☐ Same as Proband	Address	City	State	Zip	Relationship to proband

SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)

☐ Personal history of allogenic bone marrow or peripheral stem cell transplant ☐ Current diagnosis of heme malignancy, Type:

Collection Date	Specimen ID	Medical Record #

**Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.*

Collection Assistance: ☐Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient | ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™)

*** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.*

CLINICAL INFORMATION

Does the family member have any features similar to the proband? ☐ Yes ☐ No

Describe:

SECONDARY FINDINGS (For ExomeNext and GenomeNext duo or trio orders only)

Secondary findings results are available for each family member sequenced as part of the duo or trio. Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported for this family member.

☐ Decline

FAMILY MEMBER #2 INFORMATION

Legal Name (Last, First, MI)	Date of Birth (MM/DD/YY)	Date of Death (If applicable)	Phone Number/Email

Sex Assigned at Birth: ☐F ☐M

Gender (optional) ☐Man ☐Woman ☐Nonbinary ☐Self-described

Genetic Ancestry: ☐Ashkenazi Jewish ☐Asian ☐Black/African American ☐French Canadian/Cajun ☐Hispanic/Latino ☐Mediterranean ☐Middle Eastern ☐Native American ☐Pacific Islander ☐Portuguese ☐White ☐Unknown ☐Other:

Address: ☐ Same as Proband	Address	City	State	Zip	Relationship to proband

SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)

☐ Personal history of allogenic bone marrow or peripheral stem cell transplant ☐ Current diagnosis of heme malignancy, Type:

Collection Date	Specimen ID	Medical Record #

**Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.*

Collection Assistance: ☐Phlebotomy draw** ☐ Send saliva kit to patient ☐ Send buccal kit to patient | ☐ Insurance preverification first (available for ExomeNext® and GenomeNext™)

*** As the patient's clinician, I am unaware of any potential for complication or difficulty in drawing blood for the listed patient(s). I understand that the phlebotomist has full authority to refuse to draw any patient if the safety of the phlebotomist and/or patient(s) are in question.*

CLINICAL INFORMATION

Does the family member have any features similar to the proband? ☐ Yes ☐ No

Describe:

SECONDARY FINDINGS (For ExomeNext and GenomeNext duo or trio orders only)

Secondary findings results are available for each family member sequenced as part of the duo or trio. Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported for this family member.

☐ Decline

Note: For ExomeNext or GenomeNext orders, additional relatives may be submitted for co-segregation analysis, free of charge. Please complete "Clinical Genomics Family Member TRF" if additional relatives will be included.

Ambry Genetics®
A TEMPUS COMPANY

Patient Name: _____ DOB: _____

Clinical Genomics Test Requisition Form - Page 3 of 6

INDICATION(S) FOR TESTING

ICD-10 code(s):	Will medical management change depending upon the results of the test? ☐ Yes ☐ No

PROBAND'S PRIMARY INDICATION FOR TESTING

Please describe in a few words the main reason for ordering exome or genome testing (Please also provide clinic notes and pedigree):

PROBAND'S CLINICAL OVERVIEW (Check yes for all that apply)

☐ Yes ☐ No Audiologic/Otolaryngologic
☐ Yes ☐ No Cardiovascular
☐ Yes ☐ No Craniofacial
☐ Yes ☐ No Dental
☐ Yes ☐ No Dysmorphic Features
☐ Yes ☐ No Dermatologic
☐ Yes ☐ No Endocrine
☐ Yes ☐ No Fetal (*Please complete and attach the Prenatal Form*)
☐ Yes ☐ No Gastrointestinal
☐ Yes ☐ No Genitourinary
☐ Yes ☐ No Growth Disorders:
  ☐ Yes ☐ No Undergrowth
  ☐ Yes ☐ No Overgrowth
  ☐ Yes ☐ No Failure to thrive
☐ Yes ☐ No Hematologic
☐ Yes ☐ No Immunologic/Infectious/Allergy
☐ Yes ☐ No Metabolic/Biochemical
☐ Yes ☐ No Movement Disorder
☐ Yes ☐ No Musculoskeletal/Structural
☐ Yes ☐ No Multiple Congenital Anomalies
☐ Yes ☐ No Neurologic
  ☐ Yes ☐ No Seizures/Epilepsy
  ☐ Yes ☐ No Autism Spectrum Disorder
  ☐ Yes ☐ No Developmental Delay/Intellectual disability
  ☐ Yes ☐ No Ataxia/Spasticity
  ☐ Yes ☐ No Psychiatric
  ☐ Yes ☐ No Abnormal brain MRI
☐ Yes ☐ No Obstetric
☐ Yes ☐ No Oncologic
☐ Yes ☐ No Ophthalmologic
☐ Yes ☐ No Pulmonary
☐ Yes ☐ No Renal
☐ Yes ☐ No Tone abnormalities
  ☐ Yes ☐ No Hypotonia
  ☐ Yes ☐ No Hypertonia

ADDITIONAL CLINICAL DETAILS

Autism: ☐ no autistic behaviors ☐ autistic behaviors (describe): _____

Dysmorphic Features (describe): _____

Congenital Anomalies (describe): _____

History of Seizures ☐ Yes ☐ No ☐ diagnosed epilepsy Seizure type(s):_____

Progressive disease ☐ Yes ☐ No

Previous Studies

MRI/CT studies (findings): _____

Chromosome analysis: _____ Microarray analysis:_____

Other molecular studies:_____

Growth Indices (current): Head circumference: _____% Weight: _____ % Height: _____%

Differential diagnosis/Genes of interest:_____

Previously Reported Variants: *See instructions for reporting of Previously Reported Variants on the Supplemental Information Page*

Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____

Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____

Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____

FAMILY HISTORY (Please attach pedigree)

Is anyone in the family affected with a similar phenotype as the proband? ☐ NO ☐ YES, please list exact relationship to proband, symptoms and age of onset of symptoms:

_____

_____

Is there any consanguinity (conception between blood relatives) in the family? ☐ NO ☐ YES If yes please describe: _____

_____

Known Familial Variant: Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____

Ambry Genetics®
A TEMPUS COMPANY

Patient Name: _____ DOB: _____

Clinical Genomics Test Requisition Form - Page 4 of 6

Please check the box next to the test(s) being ordered below. If this TRF is sent to Ambry without or ahead of the sample, it will be treated as a preverification. If test ordered is different than the test preverified, we will honor what is on the TRF order form with the sample. Preverification will only be performed for ExomeNext® and GenomeNext™ testing.

For Reflex or Concurrent Testing: See Reflex or Concurrent Testing section of the Supplemental Information page.

Test 1: _____ ☐ Reflex to ☐ Concurrent with Test 2: _____ ☐ Reflex to ☐ Concurrent with Test 3: _____

Check	Test Name	Test Code	Description
Exome			
!	**REQUIRED: Select a Primary Test Order**		
☐	ExomeNext® ☐ Proband only ☐ Duo ☐ Trio	9900	Exome sequencing
☐	ExomeNext-*Rapid*®	9999-R	Rapid trio exome sequencing including a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)
ExomeNext Supplemental Test Options *(Primary test order required. See descriptions for details.)*			
	ACMG Secondary Findings* ☐ Decline	9920	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.
☐	ExomeReveal® RNA Analysis	9990	RNA analysis is available with all ExomeNext orders except for ExomeNext-*Rapid*. EDTA and PAX-gene RNA tubes are required.
☐	Mito DNA	9900-M	Analysis of a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)
Genome			
!	**REQUIRED: Select a Primary Test Order**		
☐	GenomeNext™ ☐ Proband only ☐ Duo ☐ Trio	7000	Genome sequencing including sequencing of mitochondrial DNA (mtDNA)
GenomeNext Supplemental Test Options *(Primary test order required.)*			
	ACMG Secondary Findings* ☐ Decline	7002	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.
☐	GenomeReveal™ RNA Analysis	7004	RNA analysis is available with all GenomeNext orders. EDTA and PAX-gene RNA tubes are required. Genome Reveal will be added automatically if a PAX tube is provided.
Fragile X syndrome and Chromosomal Microarray			
☐	Fragile X syndrome	4544	*FMR1* repeat expansion analysis and methylation studies
☐	SNP Array	5490	Chromosomal microarray (>2.6 million copy number probes and 750,000 SNP probes)

**Secondary Findings: Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported.*

☐ **Opt-in to Reporting of Variants of Unknown Significance (for Exome-based Neurology panels only)**

For patients undergoing an epilepsy or neurodevelopmental disorder panel listed below, checking this box indicates that VUS(s) identified on the test(s) ordered will be reported for this patient. If you do not check this box, VUS(s) will not be reported.

☐ **Parental samples provided for cosegregation**

Cosegregation testing of family members is available for the epilepsy and neurodevelopmental disorder panels listed below.

Check	Test Name	Test Code	Description
Epilepsy			
☐	EpilepsyNext®	6864	Multigene panel test for epilepsy
☐	EpilepsyNext-*Expanded*™	6865	Multigene panel test for genes associated with seizures, primarily with neonatal to childhood onset
Neurodevelopmental Disorders			
☐	AutismNext®	6863	Multigene panel test for non-syndromic autism spectrum disorders and/or intellectual disability
☐	Neurodevelopment-Next™	6861	Multigene panel test for genes known to cause developmental delay, intellectual disability, and/or autism spectrum disorders

Additional Neurology Testing Options

Testing is available for *PTEN, TTR*, neurocutaneous, and neuro-oncology disorders (such as neurofibromatosis and tuberous sclerosis) using our Comprehensive requisition form available at www.ambrygen.com/providers/forms

OTHER ORDER

Please visit ambrygen.com/tests for details.

Test Code: _____ Test Name: _____

KNOWN VARIANT ANALYSIS (Please include a copy of relative's report)

Gene(s): _____ Variant(s) (c. and/or p.): _____

Relative Name: _____

Relationship to Relative: _____ Accession # (If tested at Ambry): _____

Positive control sample: ☐ will be provided ☐ already at Ambry ☐ not available

FOR PRENATAL SPECIMENS, POC OR CORD BLOOD: MATERNAL CELL CONTAMINATION ANALYSIS REQUIRED Both test codes required for fetal specimens.

☐ 1260 MCC for amniotic fluid culture, CVS, or cord blood
☐ 1262 MCC Reference for maternal blood sample (No Charge)

Notes:

CONTACT INFORMATION

For ExomeNext and GenomeNext™ preverification requests please send the Medical Necessity Form and Clinical Genomics TRF to preverification@ambrygen.com or fax to 949-900-5501.

All other documents can be secure uploaded at ambrygen.com/secure-upload, or faxed to 949-900-5501.

AmbryPort is a secure client portal that allows order submission, test status updates, insurance authorization status and report downloads. All required documents can be completed and directly uploaded through AmbryPort during the ordering process or after order submission. Please visit portal.ambrygen.com/signup to sign up.

Ambry Genetics®
A TEMPUS COMPANY

Supplemental Information - Page 5 of 6

Electronic ordering is also available via AmbryPort®. Please visit https://portal.ambrygen.com/login to log in to the online portal.

ORDERING CHECKLIST (Required)
☐ Proband specimen
☐ Clinical Genomics TRF with patient & clinician signatures
☐ Clinical history (attach clinic notes)
☐ Medical Necessity Form (insurance orders only)
☐ Copy of Insurance Card (insurance orders only)
Orders with missing requirements will be placed on hold until all requirements are received.
ORDERING CHECKLIST (Recommended)
☐ Family member specimens *Please send all first degree and other informative relatives within 4 weeks of the order.*
☐ Family history or pedigree
☐ Previous test results

Neurology Multi-Gene Tests

For current neurology panel gene content, please visit www.ambrygen.com/providers/neurology/test-menu (linked to QR code below)

Scan for current neurology panel gene content

Specimen Requirements

Blood/saliva/buccal swab sample from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva/buccal swab sample from patients with active hematological disease is not recommended. An alternative specimen may be needed. See ambrygen.com/specimen-requirements for details.

Fetal specimens, cord blood and POC will have maternal cell contamination studies added for a charge. Maternal and fetal specimen required. Please see page 4 for Maternal Cell Contamination sample submission test codes. Fetal specimens, cord blood, and POC are not accepted sample types for GenomeNext™.

ExomeNext and GenomeNext reports do not include comments about the presence or absence of clinically validated known **familial variant(s)**. Exome-based neurology panels include a comment if absent.

Previously Reported Variants

ExomeNext® or GenomeNext™ report comments about the presence or absence of a variant previously reported **in the patient** require the "Previously Reported Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- Name and date of birth

Previously reported variant requests without an internal Ambry reference ID or positive lab report will not receive a variant-specific report comment.

ExomeNext and GenomeNext reports do not include comments about the presence or absence of clinically validated known familial variant(s). Exome-based neurology panels include a comment if absent.

Reflex or Concurrent Testing

Concurrent testing is when multiple tests are initiated at the same time. When multiple tests are ordered on the same test requisition form, testing will be run concurrently unless otherwise specified.

Reflex testing is when a subsequent test is initiated pending the outcome of the initial test. Reflex testing may result in delayed reporting of results.

For reflex test orders:

- Any diagnostic finding at any step will result in cancellation of any subsequent reflex tests.
- Non-diagnostic findings (including VUS or Uncertain results) will automatically reflex to the subsequent test.
- Secondary findings results do not impact whether a subsequent test is initiated or canceled.

Ambry Genetics®
A TEMPUS COMPANY

Patient Name: _____ DOB: _____

ExomeNext Medical Necessity Form - Page 6 of 6

REQUIRED FOR INSURANCE ORDERS ONLY (NOT REQUIRED FOR CIGNA MEMBERS)

This form is required if you are ordering Exome testing and wish to have the patient's insurance billed. Please complete and submit with the TRF and a copy of clinical notes. This form replaces the Letter of Medical Necessity.

1. Has the patient had previous Whole Exome Sequencing (WES) performed?

☐ Yes, date performed: _____

☐ No

2. Does this patient have a clinical presentation consistent with the following (select all that apply):

☐ Multiple abnormalities affecting unrelated organ systems (please specify): _____

OR two of the following:

☐ Abnormality affecting a single organ system(specify): _____

☐ Significant intellectual disability, symptoms of a complex neurodevelopmental disorder (i.e. self-injurious behavior, reverse sleep-wake cycle, or seizure/epilepsy), or severe neuropsychiatric condition (e.g. schizophrenia, bipolar, Tourette syndrome)

☐ Family history strongly implicating a genetic etiology (please specify findings and relationships): _____

☐ Period of unexplained developmental regression (unrelated to autism or epilepsy)

3. Are the results of this WES test expected to directly influence this patient's medical management recommendations and clinical outcome?

☐ Yes (please describe): _____

☐ No

4. Please describe the genetic tests that would be indicated if WES were NOT performed (i.e., single gene tests, gene panels, etc.):

☐ Chromosomal microarray

☐ Single gene test(s): _____

☐ Multigene panel(s): _____

☐ Other genetic test(s): _____

5. Please describe follow-up procedures & frequency that would be needed if WES were NOT performed (i.e., lumbar puncture, imaging studies, brain MRI, etc.):

☐ Imaging study: _____

☐ Surgery: _____

☐ Biopsy: _____

☐ Other: _____

7 Argonaut, Aliso Viejo, CA 92656 USA Toll Free +1.866.262.7943 Fax +1.949.900.5501 **ambrygen.com**
©2026 Ambry Genetics Corporation. All rights reserved. Ambry Genetics® is a registered trademark of Ambry Genetics Corporation.
MKT-SPEC-TRF-50002-EN_v35 10.26.26